COSA 2015* , ,
Presentations this author is a contributor to:
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes (#189)
3:00 PM
Toni K Choueri
Posters1
Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) (#204)
3:00 PM
James Larkin
Posters1